

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L29            0 L28

=> fill reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.31	861.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-12.49

FILE 'REGISTRY' ENTERED AT 14:26:37 ON 13 MAR 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 12 MAR 2001 HIGHEST RN 326849-80-3  
DICTIONARY FILE UPDATES: 12 MAR 2001 HIGHEST RN 326849-80-3

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

37534  
**SEARCH REQUEST FORM**

U.S. DEPARTMENT OF COMMERCE  
 Patent and Trademark Office

Requestor's  
 Name:

BERCH

Serial  
 Number:

554077

Date:

3/13/01

Phone:

478

Art Unit:


1624

4D5

**Search Topic:**

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

W = NH<sub>2</sub> or NO<sub>2</sub>



J = C, but not

Q = (CH<sub>2</sub>)<sub>1-3</sub> or

Point of Contact:  
 Mary Hale  
 Technical Info. Specialist  
 Chm 12D16 Tel: 303-4258

H202

**STAFF USE ONLY**

Date completed:

3/13

Searcher:

Wang

Terminal time:

30

Elapsed time:

8

CPU time:

Total time:

Number of Searches:

Number of Databases:

Search Site

STIC

CM-1

Pre-S

Type of Search

N.A. Sequence

A.A. Sequence

Structure

Bibliographic

Vendors

IG

STN

Dialog

APS

Geninfo

SDC

DARC/Questel

Other

1  
TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000


Please note that search-term pricing ~~does~~ apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d 128 que stat;d 1-4 ide cbib abs

L26

STR



W= VAR G1=NH2/NO2

Q= REP G2=(1-3) C

VPA 17-13/14/15 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L28 4 SEA FILE=REGISTRY SSS FUL L26

100.0% PROCESSED 57 ITERATIONS

SEARCH TIME: 00.00.04

4 ANSWERS

L28 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2001 ACS

RN 285140-23-0 REGISTRY

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, dimethylcarbamate (ester)


(9CI) (CA INDEX NAME)

Prepared by M. Hale 308-4258

Page 22

FS STEREOSEARCH  
MF C16 H16 Cl N5 O6  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:120681 Preparation of amino acid acyl derivatives as inhibitors of leukocyte adhesion mediated by VLA-4. Konradi, Andrei; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker, Gregory

S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant, Francine S.; Semko, Christopher; Xu, Ying-Zi (Elan Pharmaceuticals, Inc., USA; American Home Products). PCT Int. Appl. WO 2000043372 A1 20000727, 342 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US1686 20000121.

PRIORITY: US 1999-PV116923 19990122; US 1999-PV160999 19991021.  
AB Disclosed are compds. R2-W:CR1-Q-CR3R3'COX and R2-W'-CHR1-Q-CR3R3'COX [R1 and R2 are joined to form a ring; R3, R3' = H, iso-Pr, -CH2Z or :CHZ, where Z = H, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = O, S, SO, SO2, NH or imino group; W = nitrogen, carbon; W' = nitrogen, carbon, oxygen, sulfur, SO, SO2; X = OH, (un)substituted alkoxy, alkenoxy, cycloalkoxy, cycloalkenoxo, aryloxy, heteroaryloxy or heterocyclyloxy, an amino group] which bind VLA-4.

Thus, N-[5-(N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester was prep'd. by condensation

of L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester with 2,4-dichloro-5-nitropyrimidine, followed by nitro group redn. and tosylation. Compds. synthesized in the examples are expected to have a binding affinity to VLA-4 expressed by an IC50 of 15 .mu.M or less.


L28 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2001 ACS

RN 285139-31-3 REGISTRY Prepared by M. Hale 308-4258

Page 23

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, 1,1-dimethylethyl ester,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H24 Cl N5 O6  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:120681 Preparation of amino acid acyl derivatives as  
inhibitors of leukocyte adhesion mediated by VLA-4. Konradi, Andrei;  
Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker,

Gregory

S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant,  
Francine S.; Semko, Christopher; Xu, Ying-Zi (Elan Pharmaceuticals, Inc.,  
USA; American Home Products). PCT Int. Appl. WO 2000043372 A1 20000727,  
342 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,  
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,  
TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US1686

20000121.

PRIORITY: US 1999-PV116923 19990122; US 1999-PV160999 19991021.

AB Disclosed are compds. R2-W:CR1-Q-CR3R3'COX and R2-W'-CHR1-Q-CR3R3'COX [R1  
and R2 are joined to form a ring; R3, R3' = H, iso-Pr, -CH2Z or :CHZ,  
where Z = H, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl,  
carboxy, carboxyalkyl, etc.; Q = O, S, SO, SO2, NH or imino group; W =  
nitrogen, carbon; W' = nitrogen, carbon, oxygen, sulfur, SO, SO2; X = OH,  
(un)substituted alkoxy, alkenoxy, cycloalkoxy, cycloalkenoxo, aryloxy,  
heteroaryloxy or heterocyclyloxy, an amino group] which bind VLA-4.

Thus,

N-[5-(N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-  
dimethylcarbamyloxy)phenylalanine tert-Bu ester was prepd. by


condensation

of L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester with  
2,4-dichloro-5-nitropyrimidine, followed by nitro group redn. and

tosylation. Compds. synthesized in the examples are expected to have a  
Prepared by M. Hale 308-4258 Page 24

binding affinity to VLA-4 expressed by an IC50 of 15 .mu.M or less.

L28 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2001 ACS  
RN 225100-33-4 REGISTRY  
CN 4,5-Pyrimidinediamine, 2-chloro-N4-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-6-methyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H23 Cl N4 O2  
SR CA  
LC STN Files: CA, CAPLUS



2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:350245 Preparation of purine derivative dihydrate as phosphodiesterase IV inhibitor. Sekiya, Kouichi; Takemiya, Akihiro; Ohshima, Masahiro (Mitsubishi Chemical Corporation, Japan). PCT Int. Appl. WO 2000068231 A1 20001116, 29 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP2952 20000509. PRIORITY: JP 1999-129499 19990511.


AB Claimed is a dihydrate of 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurin]-2-yl]-3-oxypropylpyridine N-oxide (I); also claimed are : (a) pharmaceutical contg. I as active ingredient; (b) pharmaceutical contg. I as active ingredient for the treatment of asthma, chronic obstructive lung disease and/or other inflammatory diseases; (c) phosphodiesterase IV inhibitor contg. I (d) and intermediates for I. I

in vitro showed IC50 of  $3.4 \times 10^{-9}$  M against phosphodiesterase IV, vs. IC50 of  $5 \times 10^{-7}$  M shown by rolipram.

REFERENCE 2: 130:352279 Preparation of purine derivatives as antiasthmatics.


Tanaka, Toshihiko; Iwashita, Eiichirou; Tarao, Akiko; Amenomori, Akira; Ono, Yuya (Mitsubishi Chemical Corporation, Japan). PCT Int. Appl. WO 9924432 A1 19990520, 148 pp. DESIGNATED STATES: W: CA, CN, GB, KR, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP5092 19981112. PRIORITY: JP 1997-310365 19971112.

GI



AB Title compds. I and II (R1 = alkyl, CHF2; R2 = tetrahydrofuranyl, alkyl, haloalkyl, alkenyl, cycloalkyl, etc.; R3 = H, halo, OH, alkyl, alkoxy, amino, alkylamino, dialkylamino, etc; R4, R5 = H, halo, alkyl, alkoxy, amino, alkylamino, pyrrolidinyl, morpholino, dialkylamino, etc; X = H, halo, NO2) and their salts, useful as antiasthmatics, were prepd. 2-Chloro-9-[[3-(cyclopentyloxy)-4-methoxy]benzyl]-6,8-dimethylpurine showed IC50 of  $6.7 \times 10^{-9}$  M against phosphodiesterase IV. Formulations contg. title compds. were given.

L28 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2001 ACS  
 RN 225100-31-2 REGISTRY  
 CN 4-Pyrimidinamine,  
 2-chloro-N-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-  
 6-methyl-5-nitro- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H21 Cl N4 O4  
 SR CA  
 LC STN Files: CA, CAPLUS



2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:350245 Preparation of purine derivative dihydrate as phosphodiesterase IV inhibitor. Sekiya, Kouichi; Takemiya, Akihiro; Ohshima, Masahiro (Mitsubishi Chemical Corporation, Japan). PCT Int. Appl. WO 2000068231 A1 20001116, 29 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP2952 20000509. PRIORITY: JP 1999-129499 19990511.


AB Claimed is a dihydrate of 4-[[9-[[3-(cyclopentyloxy)-4-methoxy]benzyl]-6,8-dimethylpurin]-2-yl]-3-oxypropylpyridine N-oxide (I); also claimed are :  
 Prepared by M. Hale 308-4258 Page 26

(a) pharmaceutical contg. I as active ingredient; (b) pharmaceutical contg. I as active ingredient for the treatment of asthma, chronic obstructive lung disease and/or other inflammatory diseases; (c) phosphodiesterase IV inhibitor contg. I (d) and intermediates for I. I in vitro showed IC50 of  $3.4 \times 10^{-9}$  M against phosphodiesterase IV, vs. IC50 of  $5 \times 10^{-7}$  M shown by rolipram.

REFERENCE 2: 130:352279 Preparation of purine derivatives as antiasthmatics.

Tanaka, Toshihiko; Iwashita, Eiichirou; Tarao, Akiko; Amenomori, Akira; Ono, Yuya (Mitsubishi Chemical Corporation, Japan). PCT Int. Appl. WO 9924432 A1 19990520, 148 pp. DESIGNATED STATES: W: CA, CN, GB, KR, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP5092 19981112. PRIORITY: JP 1997-310365 19971112.

GI



AB Title compds. I and II (R1 = alkyl, CHF2; R2 = tetrahydrofuranyl, alkyl, haloalkyl, alkenyl, cycloalkyl, etc.; R3 = H, halo, OH, alkyl, alkoxy, amino, alkylamino, dialkylamino, etc; R4, R5 = H, halo, alkyl, alkoxy, amino, alkylamino, pyrrolidinyl, morpholino, dialkylamino, etc; X = H, halo, NO2) and their salts, useful as antiasthmatics, were prepd. 2-Chloro-9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurine showed IC50 of  $6.7 \times 10^{-9}$  M against phosphodiesterase IV. Formulations contg. title compds. were given.

=> fil caold;s 128

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	149.08	860.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.24	-12.49

FILE 'CAOLD' ENTERED AT 14:26:32 ON 13 MAR 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

Prepared by M. Hale 308-4258

Page 27